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Abstract
Albeit the rapidly evolving knowledge about tumor biochemistry enables various new
drug molecules to be designed as treatments, malignant central nervous system (CNS)
tumors  remain  untreatable  due  to  the  failure  to  expose  the  entire  tumor  to  such
therapeutics at pharmacologically meaningful quantities. Therefore, drug delivery in
CNS tumors must be properly addressed, as otherwise, novel therapies will continue
to fail. In this regard, nanomedicine poses an appealing platform for efficient drug
delivery to the CNS, since it may be targeted to improve the drug availability in the site
of action, which would be translated into lower drug doses and fewer side effects.
Hence, the accumulation of data about the CNS physiology and their relevant receptors,
the widening therapeutic armamentarium of drugs potentially useful in CNS chemo‐
therapy and the alternative routes for administration may envisage nanomedicines as
a forthcoming routine approach. Indeed, on the basis of the promising results gathered
from preclinical studies of nanomedicine‐based therapy both systemically and locally
administered, some nanomedicines have already been approved for clinical trials in a
variety  of  CNS  tumor  conditions  to  serve  as  the  first  steps  in  the  translation  of
nanotherapy to clinic. Their outcome will steer research directions for further improve‐
ments.
Keywords: central nervous system tumors, chemotherapy, brain targeting, clinical tri‐
als, local delivery, systemic delivery
1. Introduction
Primary central nervous system (CNS) tumors represent 2% of all cancers in adults, whereas
this percentage increases to 15–25% in children. Primary brain tumors are stratified by the World
Health Organization (WHO) according to a “malignancy scale”. The WHO grade is closely
related to clinical prognosis, ranging from grade I (with low proliferative potential and the
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possibility of cure following surgical resection alone) to grade IV (with widespread invasion of
the surrounding healthy tissue, high proliferative potential, recurrence and fatal outcome).
Unfortunately, many low‐grade gliomas eventually often show progression to a higher histologic
grade [1].
Gliomas represent approximately 80% of all malignant primary brain tumors. Glioblastomas
(WHO grade IV) are the most frequent (54.4%) and aggressive type of glioma [2], although, in
terms of treatment, WHO grade III brain tumors and glioblastomas are clustered together and
treated similarly.
Although the management of brain tumors depends on the time of diagnosis, new onset or
recurrence, the performance status and the age of the patient, the current standard approach
in high‐grade brain tumors combines maximal surgical resection (if eligible) with radiotherapy
and concomitant and adjuvant chemotherapy as well as symptomatic treatment [3].
Available chemotherapy for high‐grade brain tumors includes temozolomide, nitrosureas
[carmustine (BCNU) and lomustine (CCNU)], topoisomerase inhibitors (etoposide, irinote‐
can), platinum agents (carboplatin), procarbazine, and vincristine. The first‐line chemotherapy
for newly diagnosed glioblastoma multiforme consists of temozolomide, whereas carmustine
represents the second‐line treatment. After the approval of temozolomide in 1999, irinotecan,
etoposide, and platinum agents are mostly used only as adjuvant chemotherapy of bevacizu‐
mab (FDA approved in 2009 in monotherapy) for recurrent glioblastomas. In the case of WHO
grade III gliomas (anaplastic astrocytomas and oligodendrogliomas), the first‐line treatment
is the PCV (procarbazine‐lomustine‐vincristine) combination [4].
Unfortunately, the efficacy of the treatment of brain tumors is questionable, since recurrence
happens within 6.9 months of initial diagnosis. As a result, despite the combination of surgical
resection, radiotherapy and concomitant temozolomide, glioblastoma multiforme remains
incurable with a poor median survival of 14.6 months and 2‐year survival rate of 26.5% [5].
This poor prognosis results from chemotherapy tumor resistance [6].
One of the chemoresistance mechanism best characterized relates to the expression of O6‐
methylguanine‐DNA methyltransferase (MGMT), a repair gene that removes alkyl groups
from the O6 position of guanine and consequently counteracts the alkylating agents (temozo‐
lomide or nitrosureas). Methylation of the promoter of this gene, which occurs in 35–45% of
the cases, makes glioblastoma more sensitive to alkylating agents [7, 8].
Likewise, the existence of glioma stem cells greatly accounts for tumor recurrence, since they
upregulate the expression level of P‐gycoprotein [9], which is responsible for active efflux of
many chemotherapy agents, including temozolomide.
The overexpression of epidermal growth factor receptor (EGFR), which ultimately triggers the
activation of complex alternative signaling pathways, aimed at inhibiting apoptosis, also
contributes to resistance to standard chemotherapy. Unfortunately, none of the receptor
tyrosine kinase inhibitors and signal transduction inhibitors tested in clinical trials prolonged
the mean survival, mainly due to the lack of successful drug delivery across the blood‐brain
tumor barrier (BBTB), since the exposure of the tumor to sublethal drug concentrations helps
select the drug‐resistant tumor cells [10].
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The BBTB consists of the endothelium of existing and abnormal angiogenic blood vessels that
deliver nutrients and oxygen to the tumor and enable widespread glioma migration to brain
areas where the function of the barrier is still intact. Therefore, even though the BBTB is
considered dysfunctional, the truth is that in low grade and in the infiltrative parts of high‐
grade gliomas, often responsible for the recurrence, the BBTB closely resembles the tight blood‐
brain barrier (BBB) typical of healthy brain capillaries [11]. Hence, the BBTB greatly accounts
for the failure rate of the brain tumor therapy, since the hindrance to brain delivery of chemo‐
therapeutic agents at pharmacologically effective levels conferred by this barrier cannot be
offset by dose increase for fear of systemic toxicity. Furthermore, drug efflux pumps of the BBB
can also be expressed in endothelium at the BBTB, representing an additional constraint to the
achievement of adequate drug levels at the target site [12].
Since the therapeutic potential of chemotherapy greatly depends on its ability to attain
pharmacologically effective levels at the entire diseased brain area, novel strategies to enhance
drug delivery at the tumor site are strongly needed.
2. The nanomedicine approach
Conventional chemotherapy has failed to improve the prognosis of CNS tumors; hence novel
drug delivery technologies have emerged under the assumption that targeted drug delivery
could contribute to expose the entire tumor to therapeutically meaningful levels and ultimately
improve treatment outcomes for brain tumors. An example of the success achievable thanks
to advances in pharmaceutical technology is Gliadel®, the first FDA‐approved brain cancer
treatment to deliver chemotherapy directly to the tumor site in patients with malignant glioma
for whom surgical resection is indicated. Gliadel® is a biodegradable wafer implanted on the
surface of the resected tumor beds at the time of surgery that delivers carmustine steadily for
about 3 weeks directly to the tumor site minimizing drug exposure to other areas of the body.
Gliadel® contributes to eradicate the residual tumor cells at the resection margin and com‐
plements other standard therapies for brain tumors (surgery and radiotherapy) [13].
Nanomedicine represents an encouraging trend within the field of novel drug delivery
technology with potential to preferentially delivering the drug at the target site and conse‐
quently overcoming biodistribution and pharmacokinetic limitations that eventually account
for treatment failure of brain tumors. Nanomedicine is the application of nanotechnology in
view of making a medical diagnosis or treating or preventing diseases. It exploits the improved
and often novel properties of materials at a nanoscale. Nanomedicines are colloidal structures
that act as drug carriers in which the drug substance is dissolved, entrapped, or encapsulated,
or to which the drug substance is adsorbed or attached [14]. Unlike monolithic implants such
as Gliadel®, colloidal carriers can be administered with conventional needles and therefore
are not limited to those brain tumors where surgical resection is indicated.
Nanomedicine is especially relevant for chemotherapeutic agents, whose low dose availability
at the tumor site cannot be counterbalanced by dose increase for fear of severe systemic side
effects. Targeted nanomedicines would improve the availability of the drug at the scattered
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tumor bed and would allow obtaining therapeutic effects with lower drug doses and concom‐
itantly minimizing the side effects of chemotherapy not only in unwanted peripheral tissues,
but also in healthy brain cells. Therefore, the therapeutic index of drugs would be greatly
enhanced thanks to nanomedicine. Targeted drug delivery to the site of action can be achieved
through passive and active targeting or even through external physical stimuli. Passive
targeting exploits the specific anatomical and functional features of the target tissues or cells
to deliver drugs to the site of action. Active targeting requires the conjugation of tissue or cell‐
specific ligands on the surface of nanocarriers, whose recognition would eventually allow
preferential accumulation of the drug at the diseased site. External stimuli such as a magnetic
field, focused ultrasounds, light, and heat can also help selectively release the drug payload
of nanomedicines at the target site [15].
Moreover, whereas most anticancer drugs are hydrophobic and often require to be solubilized
in organic solvents for conventional administration, nanomedicines provide alternative
formulations to administer chemotherapy without the need to use toxic solvents. Furthermore,
nanomedicine is opening new therapeutic opportunities for easily degradable drug substances
that cannot be used effectively as conventional formulations due to their short half‐lives in
vivo. Nanomedicines not only shield such drugs from enzymatic and chemical drug cleavage
that accounts for the loss of pharmacological effect, but also can sustain and/or trigger drug
release at a specific rate at the target site, resulting in maintenance of drug levels within a
therapeutically desirable range. Thanks to this controlled release profile, undesirable phar‐
macokinetic properties of drug substances can be overcome with the use of nanocarriers and
the dosing frequency can be improved to prescribe more comfortable dose regimens for
patients.
The nanomedicine approach to enhance drug delivery to CNS tumors is highly versatile, since
it would allow the coadministration of different anticancer agents and is compatible with both
local and systemic routes of administration. In the current scenario, this approach must be
directed toward surpassing acquired resistance to conventional chemotherapy and imple‐
menting strategies to boost the distribution across the brain endothelium in the case of systemic
administration [16].
Nevertheless, nanomedicines might likewise cause unexpected toxicities as the other exci‐
pients also reach target tissues along with the drug. Nondegradable nanomedicines used for
drug delivery would accumulate at the tumor site and would ultimately result in chronic
inflammatory response, because, as colloidal systems, there is no chance of removing them
after completion of the treatment. Albeit toxicity concerns of nanomedicines greatly rely on
the relatively unexplored size‐dependent properties and interaction with biological structures
that strikingly differ from those of the bulk material, it is broadly agreed that the safety profile
of brain‐targeted nanomedicines would be improved with biocompatible excipients devoid of
any short or long‐term toxic effects [17]. Consequently, despite the large number of available
biomaterials for nanomedicines preparation, only a few are suitable for brain tumor treatment
because the CNS requires conservative choices with a proven track record of clinical safety.
Nanomedicines developed for brain delivery mainly belong to three categories: polymer‐
based, lipid‐based and metal‐based, according to their major excipient (Table 1).
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Category Nanocarrier Description Size (nm) Phase of
development
Polymer‐
based
Polymeric
nanoparticles
Solid matrix‐like or reservoir‐like nanostructures
made up of biocompatible and biodegradable
polymers or copolymers
20–1000 Preclinical
Polymeric
micelles 
Nanostructures of amphiphilic diblock copolymers
with a core of hydrophobic blocks stabilized by a
corona of hydrophilic blocks
50–200 Preclinical
Dendrimers Highly branched tree‐like nanostructures composed
of a central core, internal branches, and reactive
terminal groups
1–10 Preclinical
Lipid‐based Liposomes Vesicles of amphipathic lipids structured in
concentric bilayers surrounding an equal number
of central aqueous compartments
80–200 Phase I, II clinical
trials
Solid lipid
nanoparticles
Solid lipid matrixes at room and body temperatures
that are stabilized by surfactant(s)
50–1000 Preclinical
Lipid
nanocapsules
Reservoir nanomedicines with a liquid oily core,
surrounded by a shell of surfactants
20–100 Preclinical
Metal‐based Magnetic
nanoparticles
Nanostructures composed of magnetic elements that
can be manipulated using magnetic fields
10–50 Preclinical
Gold
nanoparticles
Nanostructures that can serve as drug carriers and
even convert absorbed electromagnetic radiation to
heat
5–50 Preclinical
Table 1. Main types of nanomedicines that are currently under investigation for the treatment of CNS tumors.
Overall, lipid‐based nanomedicines may well be the most suitable for CNS drug delivery;
insofar as lipids have very low toxicity, are biocompatible and biodegradable by nature,
and the commercially available lipid‐based formulations show a solid track record of clini‐
cal safety [18–20], whereas at present, only a few of the studied polymers for the develop‐
ment of polymer‐based nanomedicines for brain drug delivery have demonstrated
biocompatible, biodegradable, and nontoxic properties to be approved by the FDA for clini‐
cal use [21–23]. On the other hand, since the lack of biodegradation may not be appropriate
for long‐term administration, most metal‐based nanomedicines (such as magnetic nanopar‐
ticles and gold nanoparticles) have been made more biocompatible and water‐soluble with
polymer coating [24].
3. Local delivery of nanomedicines
The local delivery of anticancer drugs serves to overcome the lack of specificity of conventional
chemotherapy. Higher drug levels at the tumor site and lower drug distribution to healthy
tissues account for the reduction of the systemic side effects with local routes of administration.
Moreover, in the case of CNS tumors, local chemotherapy bypasses the major hurdle for
systemic brain drug delivery: the blood‐brain tumor barrier. However, the mechanical breach
of this barrier may act as a double‐edged sword since this might allow neurotoxic blood
components to enter the brain or even enhance tumor dissemination.
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Nanomedicines offer several advantages over conventional chemotherapy with regard to local
CNS delivery: they can extend the exposure to short‐brain‐half‐life drugs and provide long‐
lasting drug release that ultimately maintains therapeutic levels at the target site over longer
periods. Moreover, nanomedicines show potential for enhancing antitumor activity via several
pathways. First, locally administered nanomedicines can promote passive diffusion of the
anticancer agent to the brain tumor tissue by increasing the local drug concentration gradient.
Furthermore, nanomedicines can be actively targeted to the brain tumor cells by conjugating
specific ligands that bind to the receptors that are overexpressed or uniquely expressed on the
tumor surface (a mutant form of the epidermal growth factor receptor (EGFRvIII), interleukin
receptors for interleukins 4 and 13) to efficiently trigger cellular uptake at the tumor site.
Similarly, locally administered nanomedicines can also help overcome some of the most
troublesome chemoresistance mechanisms that are eventually responsible for tumor
recurrence. In this sense, the upregulated expression of P‐glycoprotein in drug‐resistant cancer
stem cells, which accounts for active efflux of most anticancer agents from the tumor area and
reduces the effectiveness of chemotherapy, can be overcome thanks to nanomedicine. Indeed,
the coating with nonionic surfactants seems to confer the nanocarrier itself with efflux‐pump
blockage properties [25]. Additionally, along with chemotherapy, nanomedicines can serve to
deliver irreversible MGMT inhibitors (such as O6‐benzylguanine) and/or receptor tyrosine
kinase inhibitors, to sensitize brain tumor cells to alkylating agents, and to counteract the
inhibition of apoptosis mediated by the overexpression of the receptor of the epidermal growth
factor (EGFR), respectively.
Several local routes of administration may be exploited by nanomedicines for handling of CNS
tumors.
‐ The intracranial administration involves drug delivery directly into the brain parenchyma.
Nonetheless, intraoperative infusion of anticancer drugs into brain tumors has experienced
minor success given the diffusion‐limited drug distribution, which does not allow the drug to
reach the infiltrative area of recurrence. Moreover, the high interstitial fluid pressure and the
presence of edema often observed in intracranial tumors may further hinder the diffusion of
the infused agent.
Alternatively, convection‐enhanced delivery (CED), another method for intracranial adminis‐
tration, achieves larger distribution volumes in the brain, for more homogeneous distribution
within the tumor tissue, since it uses positive pressure to supplement simple diffusion with
fluid convection. CED continuously delivers a bulk flow under a pressure gradient via a
stereotactically guided catheter connected to a syringe pump. Drug leakage away from the
tumor site [especially into the subarachnoid space with the subsequent drug spreading via the
circulating cerebrospinal fluid (CSF)] should be avoided to minimize side effects such as
chemical meningitis. In this regard, the suitable placement of catheters often prevents the
leakage and helps spare healthy tissue.
CED can likewise deliver nanocarriers loaded with antineoplastic agents for CNS tumor
therapy [26]. When combined with CED, the encapsulation of the drug infused into nanocar‐
riers further reduces the potential side effects caused by drug leakage, while extends the brain
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half‐life of anticancer agents by preventing them from being rapidly metabolized and/or
eliminated by capillaries from the injection site. However, for efficient CED through the brain
interstitium, the physicochemical properties of the colloidal systems must be optimized.
First, CED‐injected nanomedicines must diffuse through interstitial spaces of the brain tissue.
Hence, the size of the colloidal systems is a critical parameter to achieve optimal distribution
volume with full coverage of the brain tumor tissue. Particles larger than 100 nm do not move
readily through the brain interstitium, are retained near the administration site and do not
distribute over clinically relevant volumes of brain tissue. Hence, in terms of size, the ideal
nanocarrier for CED should be about 20–50 nm.
Moreover, to achieve optimal distribution volumes to cover both the tumor bed and the
outlying cancer stem cells, it is convenient to provide nanocarriers with a hydrophilic coating
[mostly polyethylene glycol (PEG) [27]]. The hydrophilic coating could help mask the hydro‐
phobic structures, which would reduce the eventual binding to brain cells or to proteins in the
interstitial space and ultimately enable greater diffusion. However, hydrophilic coating of
nanocarriers also has the drawback of reducing the interactions with tumor cells, required for
the loaded anticancer drug to eradicate the tumor. Alternatively, distribution volumes can be
enhanced with the presence of co‐infusates that serve to saturate the potential binding sites
along the track of the infused nanomedicines. Furthermore, the ideal CED‐administered
nanocarrier should have a global neutral or negative charge to prevent nonspecific binding to
negatively charged structures in the brain parenchyma and to achieve larger distribution
volumes [27].
In addition, the infusion of viscous and hyperosmolar suspensions of nanocarriers would help
reduce the risk of drug leakage and enhance the distribution volume by means of osmosis‐
mediated dilatation of the interstitial space through which nanocarriers could transit, respec‐
tively.
Nonetheless, despite its remarkable potential to improve clinical outcomes for CNS tumors,
intracranial CED is an invasive neurosurgical procedure, which truly hinders its widespread
use and limits the number of dosing cycles to be applied to eligible patients.
‐ The intrathecal administration involves the injection of anticancer drugs into the intrathecal
space, which is the space that holds the cerebrospinal fluid (CSF). This can be achieved either
with the implantation of an Ommaya reservoir (a dome‐shaped container that is placed
subcutaneously under the scalp during surgery, holds the chemotherapy and delivers it into
the cerebral ventricles through a small catheter) or with direct injection into the CSF through
a numbed area of the lower part of the spinal cord. Despite the significantly less invasive
character of the second approach, intrathecal delivery fails to accumulate drugs in the brain
parenchyma due to the bulk flow rate of CSF into the venous system, making this route optimal
for the treatment of spinal tumors and disseminated meningeal metastases but not for
parenchymal tumors like glioblastoma. Indeed, since meningeal gliomatosis remain protected
by the blood‐brain barrier, intrathecal delivery is widely considered a treatment approach for
achieving improved outcomes for these patients [28].
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Encapsulated drug System Model Route of
administration
References
Irinotecan Liposomes U87‐bearing rats CED [30]
Irinotecan Liposomes GBM43‐/SF7796‐bearing mice CED [32]
Topotecan Liposomes U251‐/U87MG‐bearing rats CED [31, 36]
Topotecan + Doxorubicin Liposomes U87MG‐bearing rats CED [33]
Irinotecan + Doxorubicin Liposomes U251‐/U87MG‐bearing rats CED [34]
Camptothecin Polymer nanoparticles 9L‐bearing rats CED [46]
Temozolomide Polymer nanoparticles U87‐bearing rats CED [47]
HSVtk
(+ intraperitoneal
Ganciclovir)
Polymeric
nanoparticles 
9L‐bearing rats CED [48]
Paclitaxel
(+ radiotherapy)
Lipid nanocapsules 9L‐bearing rats CED [49]
Ferrociphenol Lipid nanocapsules 9L‐bearing rats CED [37, 38, 50]
Ferrociphenol (+
radiotherapy)
Lipid nanocapsules 9L‐bearing rats CED [51]
Metothrexate Fifth‐generation
dendrimers
F98‐bearing rats CED [42]
Cisplatin Fifth‐generation
dendrimers
F98‐bearing rats CED [43]
EGFRvIII antibody Magnetic nanoparticles U87 glioma‐bearing mice CED [39]
Cetuximab Magnetic nanoparticles NO8‐30, U87 and LN229‐
bearing mice
CED [40]
O6‐Benzylguanine
(+ oral temozolomide)
Magnetic nanoparticles GBM6‐bearing mice CED [35]
Doxorubicin Polymeric micelles 9L gliosarcoma‐bearing rats CED [41]
Synthetic retinoid Am80
(+ intraperitoneal
temozolomide)
Polymeric micelles U87 glioma‐bearing rats CED [52]
Camptothecin Polymeric micelles C6 glioma‐bearing rats Intranasal [44]
Camptothecin + siRNA
(Raf‐1)
Polymeric micelles C6 glioma‐bearing rats Intranasal [45]
Table 2. Locally‐administered nanomedicines already tested for efficacy in vivo against orthotopic rodent brain tumor
models.
Unfortunately, not all anticancer agents are suitable for intrathecal delivery, as drug spread
along the spinal canal can cause dose‐limiting chemical arachoniditis. For those irritant drug
substances, intrathecal delivery can take great advantage of nanomedicine, since their
encapsulation into nanostructures could minimize drug exposure to toxic levels. As a proof of
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it, intrathecal‐administered liposomal cytarabine (Depocyt®) has been approved for clinical
use in lymphomatous meningitis. Nonetheless, the cytotoxicity of cytarabine against a wide
spectrum of tumors makes Depocyt® a promising candidate for treating the above‐mentioned
forms of CNS cancer.
‐ More recently, the intranasal delivery has been proposed as an alternative local route of
administration. Its noninvasive nature would allow self‐administration by nasal inhalation
and would enable the sterilization procedures of the drug dosage form to be avoided. This
delivery route exploits the fact that trigeminal and olfactory nerves that innervate the nasal
epithelium represent the only direct connection between the external environment and the
brain [29]. However, this route appears to be relatively inefficient in delivering inhaled drugs
to distant brain structures, mainly due to drug loss via systemic absorption.
In regard to brain tumor therapy, intranasal administration has received minor attention, with
most applications of this approach being focused on the treatment of neurodegenerative
diseases.
Numerous locally administered drug‐loaded nanomedicines have already been assayed for
efficacy in rodent models of brain tumors: liposomes, polymer nanoparticles, lipid nanocap‐
sules, dendrimers, magnetic nanoparticles, and polymeric micelles, as summarized in
Table 2. Although results are highly variable depending on various parameters, namely the
tumor lineage and the onset, dose, and regimen of treatment, some general conclusions can be
drawn from these preclinical studies. Overall, liposomes exhibited the most noticeable survival
benefit and the presence of the highest percentage of long‐term survivors [30, 31], partly
because their potential as drug carriers was acknowledged earlier than any other alternative
nanomedicine; hence research on nanomedicines for local CNS anticancer therapy has largely
focused on liposomes.
Likewise, in some preclinical studies in rodent models, it was even evidenced that CED
outperformed the survival benefit of the same formulation administered by a peripheral
intravascular route [32]. Furthermore, the versatility of CED has enabled the coadministration
of different liposomal formulations to enhance the effect of the anticancer agents [33, 34].
Concerning CED, numerous nanomedicines were formulated with a hydrophilic coating of
polyethylene glycol and administered as slightly viscous suspensions to achieve optimal
distribution volumes that cover the whole brain tumor tissue [35]. In fact, the deprivation of
the hydrophilic coating, albeit increased median overall survival in comparison with untreated
controls, significantly differed from efficacy findings reported for animals receiving the
pegylated nanomedicines [36]. Nevertheless, it has been postulated the existence of a “thresh‐
old extent of pegylation,” over which the hindrance conferred by polyethylene glycol to
interact with the tumor cells counterbalances the increase in CED distribution volume
provided by slight pegylation [37]. On the other hand, the addition of active targeting moieties
that preferentially bind to receptors that are overexpressed on brain tumor cells to promote
the delivery of nanomedicines to their target cells is controversial: whereas the attachment of
OX26 or a cell‐penetrating peptide has shown to enhance both tumor and healthy tissue
internalization, which led to the appearance of side effects and high morbidity [38], the
attachment of chlorotoxin or antibodies that selectively bind to the epidermal growth factor
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receptor mutant (EGFRvIII) present on human glioblastoma cells achieved significant survival
benefits [35, 39, 40]. The different response could be explained by the choice of the ligand:
ligands that preferentially bind to receptors on the cerebral endothelium are pointless in local
delivery, whereas ligands that bind to receptors overexpressed on the brain tumor cells are
those to be used for active targeting in local delivery.
Moreover, some studies [41–43] evidenced the importance of an adequate drug release to
achieve a therapeutic response: the covalent linkage of methotrexate [42] and cisplatin [43] to
dendrimer structures did not lead to any improvement in the median survival time of F98‐
bearing rats due to a release failure, while the survival benefit achieved with micellar doxor‐
ubicin in 9L‐bearing rats was significantly relevant compared with CED of liposomal
doxorubicin at the same dose due to the lack of release of doxorubicin from the liposomal
formulation [41].
Importantly, CED‐administered nanocarriers have been designed to overcome the MGMT‐
related chemoresistance to alkylating agents. O6‐benzylguanine has been loaded in iron oxide
nanoparticles provided with a biocompatible chitosan‐polyethylene glycol coating and
actively targeted by chlorotoxin. The concurrent CED administration of these magnetic
nanoparticles with oral temozolomide in mice implanted with a GBM6 clinically relevant
xenograft extended by twofold the survival times in comparison with mice treated without
the MGMT inhibitor and greatly mitigated the severe myelosuppression associated with
systemic administration of free O6‐benzylguanine [35].
With regard to intranasal administration, polymeric micelles are the only nanomedicine type
tested in rodent brain tumor models [44, 45]. The attachment of the cell‐penetrating peptide
Tat on their surface for actively enhancing the penetration rate across the nasal epithelium
extended survival times [44].
4. Systemic delivery of nanomedicines
Thanks to the high brain perfusion rate, systemic intravascular administration is a very
convenient strategy in the clinical management of cancer for compatibility with repeated drug
administration and for its lower invasiveness in comparison with most local delivery routes.
However, despite being considered disrupted to some extent, the presence of the BBTB has
motivated the failure of conventional systemic chemotherapy for CNS tumors, since in low
grade and along the infiltrating areas of high‐grade gliomas where recurrences tend to occur,
the BBTB closely resembles the nonfenestrated endothelial cells typical of healthy brain
capillaries. Hence, the BBTB restricts the paracellular permeation of most anticancer agents
into the CNS. As a result, conventional systemic chemotherapy must be administered at high
drug doses, which causes severe dose‐dependent side effects in healthy nontarget tissues.
Against this background of hindrance to brain tumor delivery, nanomedicine may enhance the
distribution of poorly brain‐distributed anticancer agents across the brain endothelium, since
nanocarriers may well serve to target brain tumors through passive and active targeting or
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even through external physical stimuli [53]. Passive targeting occurs with the diffusion of
nanomedicines through the interendothelial gaps of the highly vascularized leaky BBTB in the
case of high‐grade brain tumors, a phenomenon known as the enhanced retention and
permeation (EPR) effect [54]. Moreover, surface‐modified brain actively targeted nanomedi‐
cines may also enhance CNS delivery across the intact brain endothelium of infiltrative parts
and low‐grade brain tumors by triggering transcytosis either by ligand‐receptor binding or by
electrostatic interactions [55]. Therefore, nanomedicines can be useful for the treatment of
different malignancy grades of brain tumors. In addition, the use of stimulus‐sensitive groups
to control drug release within the brain in a therapeutically relevant concentration could
further enhance the specificity of the treatment effect to the brain tumor area. Alternatively,
nanomedicines can block the active drug efflux back into the bloodstream.
For optimal passive targeting of brain tumors, systemic nanomedicines should have sufficient
circulation time [56] to take advantage of the hypervascularized, leaky, and compromised
lymphatic drainage system in a CNS tumor and selectively accumulate in the tumor tissue
through the EPR effect. When given intravascularly, the larger the nanomedicines, the more
susceptible to opsonization and removal by cells of the reticuloendothelial system (RES) [57].
Hence, to reduce opsonization in plasma and increase their plasma circulation time, the size
of nanomedicines should be maintained below 100–200 nm. Additionally, the surface coating
with hydrophilic polymers such as polyethylene glycol (PEG) to develop “stealth” nanome‐
dicines creates a hydration layer that prevents protein adsorption and evades RES clearance
[58], and consequently prolongs their circulation half‐life.
Therefore, if properly designed, nanomedicines could cross the leaky BBTB in highly malig‐
nant brain tumors by passive targeting. Moreover, the BBTB can be artificially further dis‐
rupted to enable a wider distribution of nanomedicines to the brain tumor site. This disruption
can be achieved via infusion of a hyperosmotic solution [59] or through the administration of
vasoactive agents [60]. Hyperosmotic mannitol infusions cause a transient shrinkage of
cerebrovascular endothelial cells, resulting in an enlargement of the tight junctions and BBTB
leakiness. However, mannitol infusions also increase the permeability of healthy brain tissue,
thereby increasing the risk of neurotoxicity. Conversely, the tumor vasculature is more sensitive
than healthy brain vasculature to infusions with vasoactive agents (leukotrienes, bradykinin,
and RMP‐7, an analogue of bradykinin) through the transient activation of B2 receptors.
Nevertheless, delivery of vasoactive agents requires intraarterial infusion, which increases the
invasiveness of the procedure, and thereby creates a barrier for clinical translation of this
approach. Alternatively, a local, transient, and reversible disruption of the BBTB can be
generated by low‐frequency focused ultrasound without permanent neuronal injury or other
undesired long‐term effects [61]. However, the artificial transient disruption of the BBTB is
increasingly being considered undesirable since this might lead to widespread tumor dissem‐
ination and/or to the development of seizures due to the overexposure to neurotoxic blood
components that enter the brain.
Additionally, optimal active targeting of nanomedicines would enable anticancer agents to be
delivered across fully functional BBB of infiltrative areas and low‐grade brain tumors exploit‐
ing carrier‐mediated transportation, receptor‐mediated, or adsorption‐mediated transcytosis.
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On the one hand, the carrier‐ and receptor‐mediated active targeting involves functionalizing
the surface of nanomedicines with moieties that specifically bind to receptors overexpressed
on the brain endothelium and/or brain tumor cell membranes [62]. Therefore, different
receptors in the brain could be employed:
‐ Penetration into the brain tumor area can be improved by simply targeting receptors that are
normally overexpressed on the brain endothelium (such as transferrin receptors, nicotinic
acetylcholine receptors, low‐density lipoprotein receptor (LRP1), or carriers responsible for
brain nutrient uptake) [62]. To target the transferrin receptor, both physiological ligands
(transferrin and lactoferrin) and monoclonal antibodies (OX26 and 8D3) have been attached
onto the surface of different types of nanomedicines [63–65]. Overall, physiological ligands
ensure biocompatibility and nonimmunogenicity but develop competitive phenomena with
endogenous ligands, whereas monoclonal antibodies prevent competitive phenomena with
endogenous ligands since they bind to a different epitope. Likewise, nicotinic acetylcholine
receptors have been targeted with peptides derived from snake neurotoxins, namely candoxin
and Ophiophagushannah toxin b [66–68]. The peptide angiopep‐2 has also been attached onto
the surface of several nanomedicines to target LRP1 [69, 70]. Furthermore, glucose or mannose
conjugation to nanomedicines has conferred brain‐targeting properties through overexpressed
facilitative glucose transporters [71, 72].
‐ Receptors distributed on proliferating endothelial cells in the tumor vasculature (αVβ3
integrin, aminopeptidase N, nucleolin) represent additional potential sites for active targeting
of nanomedicines to brain tumor tissue. In this sense, peptides containing the amino acid
sequence Arg‐Gly‐Asp (RGD) have been coupled to the surface of distinct nanomedicines to
bind to αVβ3 integrin [73, 74]. Another tripeptide Asn‐Gly‐Arg (NGR) has been conjugated to
different nanomedicines to target aminopeptidase N (CD 13) [75]. Moreover, the ability of the
F3 peptide and the AS1411 aptamer to bind to nucleolin has been exploited to actively target
nanomedicines to the brain tumor tissue [76, 77].
‐ Nanomedicines could also incorporate targeting moieties that bind to receptors that are
overexpressed on tumor cells, to reduce the side effects of the antitumor agent on healthy brain
cells after bypassing the BBTB. Apart from the already mentioned LRP1 and αVβ3 integrin,
these tumor targets include the receptor of the epidermal growth factor (EGFR) and its
malignant isoform EGFRvIII, receptors for interleukins 13 (IL‐13Rα2) and 4 (IL‐4R), the folate
and the insulin receptors, and even the membrane‐bound matrix metalloproteinase‐2
(MMP‐2). Consequently, antibodies to EGFR or EGFRvIII have been conjugated to several
nanomedicines for brain tumor targeting. Likewise, antiIL13Rα2 antibodies and IL‐13 or IL‐4‐
derived peptides (PEP‐1 or AP‐1, respectively) have been attached onto the surface of nano‐
medicines to selectively bind to interleukin receptors [78, 79]. To target the folate receptor, folid
acid has been used, whereas to target the insulin receptor, the monoclonal antibody 83–14 has
been incorporated to nanomedicines, since the use of the physiological ligand in this case was
truly restricted by its biological effect on nontarget regions (namely hypoglycemia) [63].
Furthermore, MMP‐2 has been widely targeted with nanomedicines coupled to a peptide
derived from scorpion venom: chlorotoxin [65, 80].
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Since any ligand for which a receptor exists on the cerebral endothelial or on the tumor cells
might be used for active targeting, the enrichment of knowledge about the transport systems
present on the BBB/BBTB and the glioma‐specific receptors would enable novel practical
approaches for improving the passage of nanomedicines to be designed with the purpose of
exposing the entire diseased brain tumor area to pharmacologically meaningful quantities.
On the other hand, the adsorption‐mediated active targeting takes advantage of electrostatic
interactions between positively charged ligands and the negatively charged sialic acid residues
in membrane glycoproteins of brain endothelial cells to trigger transcytosis. Hence, this type
of active targeting involves modifying the surface of nanomedicines to make them positively
charged, namely functionalization with cationic serum albumin and cell‐penetrating peptides.
The most frequently used cell‐penetrating peptide for functionalization of nanomedicines is
the transactivator of transcription peptide derived from HIV (TAT).
Subsequently, nanomedicines can also be designed to target simultaneously the BBB, the BBTB
and the brain tumor cells by either attaching multiple targeting moieties, or by conjugating a
single ligand that targets both the brain endothelia and the brain tumor cells [81]. In this case,
nanomedicine could indeed represent a potential platform for targeting heterogeneous brain
tumors [15].
Finally, nanomedicines can increase intratumoral concentration of systemically administered
anticancer agents by inhibiting the efflux pump function of P‐glycoprotein that is present at
the BBTB and at the infiltrative tumor cells and that actively removes these drugs, accounting
to a great extent for resistance to chemotherapy. A localized inhibition on brain efflux trans‐
porters can be achieved by co‐loading pharmacological efflux pump inhibitors (such as
tamoxifen) or by the nanomedicine itself, since the coating with nonionic surfactants seems to
provide the nanocarrier itself with efflux‐pump blockage properties.
Besides tailoring the size and surface properties of nanomedicines to influence intratumoral
accumulation, external forces such as a magnetic field, light, and heat can also help selectively
release the loaded drug of systemically administered nanomedicines at the tumor site [82].
Magnetic targeting has been applied under the assumption that magnetic nanoparticles can
accumulate within a tumor area after systemic administration with a locally applied magnetic
field. Another external force such as heat can be also used to control drug release in the case
of nanomedicines whose excipients exhibit thermosensitive properties. Apart from enhancing
tumor blood flow and vascular permeability, the application of local hyperthermia enables the
drug to be easily released from thermosensitive nanomedicines when heating over the phase‐
transition temperature of the excipients.
Numerous intravenously administered drug‐loaded nanomedicines have already been
assayed for efficacy in rodent models of brain tumors: liposomes, polymer nanoparticles, lipid
nanocapsules, dendrimers, polymeric micelles, magnetic nanoparticles, and gold nanoparti‐
cles (Table 3). Albeit results extremely depend on the tumor lineage and the onset, dose, and
regimen of treatment, some general conclusions can be drawn. In broad terms, following
intravenous administration, similar results were obtained with most types of nanomedicines.
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Encapsulated
drug
System Strategy Model References
Paclitaxel Liposomes None 9L gliosarcoma‐bearing rats [89]
Paclitaxel Liposomes ‐ Polyethylene glycol coatinga
‐ RGD peptideb
‐ Histidine rich TH peptidec
C6 glioma‐bearing mice [73]
Irinotecan Liposomes ‐ Polyethylene glycol coatinga U87MG glioblastoma‐
bearing mice
[90]
Topotecan Liposomes ‐ Polyethylene glycol coatinga
‐ Wheat germ agglutininb
‐ Tamoxifend
C6 glioma‐bearing rats [91]
Topotecan Liposomes ‐ Polyethylene glycol coatinga U87M/GBM‐43/GBM‐6
glioblastoma‐bearing mice
[92]
Doxorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ Folateb
‐ Transferrinb
C6 glioma‐bearing rats [93]
Doxorubicin Liposomes ‐ Lactoferrinb
‐ Nanocarrier cationizationc
C6 glioma‐bearing rats [94]
Doxorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ DCDX peptideb
U87MG glioblastoma‐
bearing mice
[66]
Doxorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ AP‐1 peptideb
‐ Focused ultrasounde
GBM8401 glioblastoma‐
bearing mice
[79]
Doxorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ Glutathioneb
U87MG glioblastoma‐
bearing mice
[86]
Doxorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ Hyperthermiae
C6 glioma‐bearing mice [95]
Epirubicin Liposomes ‐ Polyethylene glycol coatinga
‐ Transferrinb
‐ Tamoxifend
C6 glioma‐bearing rats [96]
Daunorubicin Liposomes ‐ Polyethylene glycol coatinga
‐ Mannoseb
‐ Transferrinb
C6 glioma‐bearing rats [72]
RNA antiEGFR Liposomes ‐ Polyethylene glycol coatinga
‐ 83‐14b
‐ 8D3b
U87MG glioblastoma‐
bearing mice
[63]
siRNA antiEGFR Liposomes ‐ Polyethylene glycol coatinga
‐ T7 peptideb
U87MG glioblastoma‐
bearing mice
[64]
DNA (pC27) Liposomes ‐ Polyethylene glycol coatinga
‐ OX26b
‐ Chlorotoxineb
C6 glioma‐bearing rats [65]
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Encapsulated
drug
System Strategy Model References
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ AS1411 aptamerb
C6 glioma‐bearing rats [77]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ Peptide 22b
C6 glioma‐bearing mice [87]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ F3 peptideb
C6 glioma‐bearing mice [76]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ PEP‐1b
C6 glioma‐bearing mice [97]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ Glucoseb
RG‐2 glioma‐bearing mice [71]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ APT peptideb
U87MG glioblastoma‐
bearing mice
[98]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ iNGR peptideb
U87MG glioblastoma‐
bearing mice
[75]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ RGD peptideb
U87MG glioblastoma‐
bearing mice
[74]
Paclitaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ Angiopepb
U87MG glioblastoma‐
bearing mice
[70]
Gemcitabine Polymeric
nanoparticles
‐ Polysorbate‐80 coatinga C6 glioma‐bearing rats [83]
Aclarubicin Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ Cationic serum albuminc
C6 glioma‐bearing rats [99]
Camptothecin Polymeric
nanoparticles
None GL261 glioma‐bearing
mice
[84]
Doxorubicin Polymeric
nanoparticles
‐ Polysorbate‐80 coatinga 101‐8 glioblastoma‐
bearing rats
[100]
Doxorubicin Polymeric
nanoparticles
‐ Polysorbate‐80/Poloxamer‐188/
Poloxamer‐908 coatinga
101‐8 glioblastoma‐
bearing rats
[101]
Doxorubicin Polymeric
nanoparticles
‐ Polysorbate‐80/Poloxamer‐188
coatinga
101‐8 glioblastoma‐
bearing rats
[102]
Docetaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ TGN peptideb
‐ AS1411 aptamerb
C6 glioma‐bearing mice [78]
Docetaxel Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ IL‐13 peptideb
U87MG glioblastoma‐
bearing mice
[103]
Porphyrin Polymeric
nanoparticles
‐ Polyethylene glycol coatinga
‐ F3 peptideb
‐ Photodynamic therapye
9L gliosarcoma‐bearing rats [104]
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Encapsulated
drug
System Strategy Model References
Ferrociphenol Lipid nanocapsules ‐ Polyethylene glycol coatinga 9L gliosarcoma‐bearing rats [85]
Doxorubicin Dendrimers ‐ Polyethylene glycol coatinga
‐ RGD peptideb
C6 glioma‐bearing mice [88]
RNA antiEGFR
(miR‐7)
Dendrimers ‐ Folateb U251 glioma‐bearing mice [105]
DNA (TRAIL) Dendrimers ‐ Polyethylene glycol coatinga
‐ Chlorotoxinb
C6 glioma‐bearing mice [80]
DNA (TRAIL) Dendrimers ‐ Polyethylene glycol coatinga
‐ Angiopepb
C6 glioma‐bearing mice [69]
DNA (TRAIL) Dendrimers ‐ Polyethylene glycol coatinga
‐ RGD peptideb
U87MG glioblastoma‐
bearing mice
[67]
Paclitaxel Polymeric micelles ‐ Polyethylene glycol coatinga
‐ CDX peptide (candoxin)b
Paclitaxel Polymeric micelles ‐ Polyethylene glycol coatinga
‐ RGD peptideb
‐ Transferrinb
U87MG glioblastoma‐
bearing mice
[106]
Paclitaxel Polymeric micelles ‐ Polyethylene glycol coatinga
‐ KC2S peptideb
U87MG glioblastoma‐
bearing mice
[68]
Paclitaxel Polymeric micelles ‐ Polyethylene glycol coatinga
‐ RGD peptideb
U87MG glioblastoma‐
bearing mice
[107]
Paclitaxel Polymeric micelles ‐ Polyethylene glycol coatinga
‐ CDX peptideb
U87MG glioblastoma‐
bearing mice
[108]
Doxurubicin +
Paclitaxel
Polymeric micelles ‐ Polyethylene glycol coatinga
‐ RGD peptideb
U87MG glioblastoma‐
bearing mice
[109]
SN‐38
(camptothecin
derivative)
Polymeric micelles ‐ Polyethylene glycol coatinga U87MG glioblastoma‐
bearing mice
[110, 111]
Paclitaxel Magnetic
nanoparticles 
‐ Magnetic fieldse C6 glioma‐bearing rats [112]
Doxorubicin Gold nanoparticles ‐ Polyethylene glycol coatinga
‐ TAT peptidec
U87MG glioblastoma‐
bearing mice
[113]
Strategies: a: passive targeting; b: carrier/receptor‐mediated active targeting; c: adsorption‐mediated active targeting; d:
inhibition of efflux pump function; e: targeting caused by external physical stimuli
Table 3. Intravenously‐administered nanomedicines already tested for efficacy in vivo against orthotopic rodent brain
tumor models.
Most nanomedicines intended for preclinical evaluation following intravenous administration
were designed to exploit passive and/or active targeting. Overall, stealth properties alone do
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not appear sufficient for enabling a nanoparticle‐mediated transport into the brain, since in
most cases of passively nonactively targeted nanomedicines survival benefits remained
extremely modest [83–85].This could be due to the fact that PEG coating also reduces the tumor
cell uptake of nanomedicines.
Additional active targeting using moieties that preferentially bind to receptors on the cerebral
endothelial cells or overexpressed on brain tumor cells did indeed improve the therapeutic
potential of nanomedicines due to preferential distribution to and within the brain tumor area:
in all the studies with intravenously administered actively targeted nanomedicines, the
median survival times were longer than their actively untargeted counterparts and noticeably
longer than the untreated controls [75, 86–88].
However, most of these receptors are ubiquitously expressed to some degree. Hence, in order
to prevent the occurrence of nonspecific side effects, dual‐actively targeted have already been
designed for achieving optimal targeting after systemic administration. In broad terms, the
preclinical studies with these dual‐targeted nanomedicines showed more extended survival
times over their monotargeted counterparts [65, 73, 78].
5. Conclusions
Despite the tremendous efforts thus far, malignant CNS tumors still represent an unmet
medical need. Albeit the rapidly evolving knowledge about tumor biochemistry enables
various new drug molecules to be designed as treatments, drug delivery in CNS tumors
deserves explicit attention, as otherwise, novel therapies will continue to fail to expose the
entire tumor and the infiltrate cells that are not located in the tumor bed to such therapeutics
at pharmacologically meaningful quantities. In this regard, nanomedicine poses an appealing
platform for efficient drug delivery to the CNS, since it may be targeted to improve the
availability of the drugs in their site of action, which could be translated into lower drug doses
and fewer side effects.
The BBTB restricts the permeation of most anticancer agents into the CNS, especially in areas
where the BBTB more closely resembles the BBB. Therefore, one major challenge in the field
of systemic chemotherapy is the development of nanomedicines that can effectively overcome
the BBTB and allow specific targeting of brain cancer cells. Overall, the features of nanomedi‐
cines dictate their biological fate: size and surface charge, the surface hydration and/or the
presence of targeting ligands on the surface. Concerning brain endothelium permeation, an
ideal systemic nanomedicine for CNS drug delivery should be around or smaller than 100 nm;
be provided with a hydrophilic coating to avoid removal by the RES, extend its plasma half‐
life and indirectly increase the likelihood of crossing the brain endothelium; have targeting
moieties to selectively enhance the distribution across the BBTB to the CNS and even be able
to inhibit the drug efflux transporters at the BBTB.
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ClinicalTrials.gov 
identifier
Condition Treatment Nanomedicine Route of
administration 
Targeting 
approach
Phase
NCT00003073u CNS tumors Cytarabine Liposome
(DepoCyt®)
Intrathecal None I
NCT00029523c Neoplastic
meningitis
Cytarabine Liposome
(DepoCyt®)
Intrathecal None Unspecified
NCT00313599c CNS tumors Paclitaxel
(+ oral lapatinib)
Albumin
nanoparticles
(Abraxane®)
Intravenous None I
NCT00019630c Brain tumors
(Children)
Doxorubicin Pegylated
liposome
(Lipodox®)
Intravenous Passive I
NCT00465673t Brain metastases Doxorubicin Pegylated
liposome
(Lipodox®)
Intravenous Passive II
NCT00734682c Glioblastoma
Gliosarcoma
Anaplastic
astrocytoma
Anaplastic
oligodendroglioma
Irinotecan Pegylated
liposome
Intravenous Passive I
NCT00854867c Neoplastic
meningitis
Cytarabine (+
concomitant/
sequential
radiotherapy)
Liposome
(DepoCyt®)
Intrathecal None I
NCT00944801c Glioblastoma Doxorubicin (+
temozolomide +
radiotherapy)
Pegylated
liposome
(Caelix®)
Intravenous Passive I/II
NCT00964743t Neoplastic
meningitis
Cytarabine
(+ oral
sorafenib)
Liposome
(DepoCyt®)
Intrathecal
(Ommaya
reservoir)
None Unspecified
NCT00992602c Leptomeningeal
metastases
Cytarabine
(+ intravenous
methotrexate)
Liposome
(DepoCyt®)
Intrathecal None II
NCT01044966t Glioblastoma
multiforme
Glioma
Astrocytoma
Brain tumor
Cytarabine
(+ oral
temozolomide)
Liposome
(DepoCyt®)
Intrathecal None I/II
NCT01222780c Brain tumors
(Children)
Vincristine Liposome
(Marqibo®)
Intravenous None I/II
NCT01386580c Recurrent
malignant glioma
Brain metastases
Doxorubicin Glutathione
pegylated
liposome
Intravenous Passive
+
Active
I/II
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ClinicalTrials.gov 
identifier
Condition Treatment Nanomedicine Route of
administration 
Targeting 
approach
Phase
NCT01563614t Leptomeningeal
metastases
Cytarabine
(+ oral
lomustine +
radiotherapy)
Liposome
(DepoCyt®)
Intrathecal None I
NCT01818713u Leptomeningeal
metastases
Doxorubicin Glutathione
pegylated
liposome
Intravenous Passive
+
Active
II
NCT02022644r High‐grade glioma Irinotecan Pegylated
liposome
CED Passive I
NCT02340156r Glioblastoma Normal human
wild type p53
DNA sequence
(+ oral
temozolomide)
Anti‐transferrin
receptor single‐
chain antibody
cationic
liposome
Intravenous Active II
Identifier of the current state of the clinical trial: u: unknown; c: completed; t: terminated; r: recruiting.
Table 4. Nanomedicines that have already reached the clinical trials stage for the treatment of CNS tumors.
Alternatively, nanomedicines can be locally administered to bypass the BBTB. However, CED
and intrathecal delivery remain invasive approaches that carry significant risks for patients.
An optimal nanomedicine for CED should be below 100 nm, neutral or negatively charged,
conjugated to specific ligands that bind the tumor cell receptors and be infused in a slight
viscous and hyperosmolar solution.
Overall, nanomedicines intended for brain delivery either for systemic or local delivery should
ideally be biocompatible and biodegradable, have a controllable release profile to trigger drug
release at the site of action, be able to be sterilized and have a feasible industrial production
for clinical implementation.
On the basis of the promising results gathered from preclinical studies of nanomedicine‐based
therapy, some nanomedicines have already been approved for clinical trials in a variety of CNS
tumors conditions to serve as the first steps in translation of nanotherapy to clinic (Table 4).
Therefore, their outcome will steer further research directions and when successful, will
provide handles for further improvements. Unfortunately, the results of the already completed
clinical trials are not yet available on clinicaltrials.gov.
It is worth underlining the fact that current clinical trials using nanomedicines for brain tumors
are conducted on patients who have failed conventional therapy and have very poor prognosis
(mostly recurrent high‐grade glioma or brain metastases). However, expanding the application
of nanomedicine to less aggressive forms of brain cancer is challenging, as long as the long‐
term side effects due to the interactions of colloids with biological structures are not yet known
and, consequently, the regulatory agencies have not yet developed comprehensive regulatory
guidelines for nanomedicines.
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In view of the approved clinical trials, some general conclusions can be drawn. On the one
hand, whereas several liposomal formulations are already under clinical trials, the rest of types
of nanomedicines are lagging behind. The investigation of nanomedicines for CNS delivery
has focused largely on liposomal preparations mostly due to the fact that their potential as
drug carriers was already acknowledged back in the 1970s, much earlier than any other
alternative nanocarrier.
On the other hand, most liposomes that reached clinical trials for the treatment of brain tumors
are passively targeted, avoiding the ligand‐receptor interaction. Despite the promising
preclinical results, translation of active targeting to clinical trials poses some challenges, since
most targeted receptors are not exclusively present at the BBTB and/or brain tumor cells, which
may give raise to side effects. Additionally, nanomedicines conjugated with physiological
ligands can develop competitive phenomena with endogenous ligands and dysregulate their
homeostasis, whereas nanomedicines that incorporate monoclonal antibodies must be able to
interact with human receptors to not cause immunogenic reactions; hence, presumably
different from those antibodies assayed in rodent preclinical models. Nonetheless, two actively
targeted liposomes have recently made their way to clinical trials to cross the BBB after
intravenous injection for achieving higher and efficacious brain drug levels: 2B3‐101 is a
PEGylated liposomal doxorubicin formulation conjugated with glutathione and SGT‐53 is a
cationic liposome conjugated with an antitransferrin receptor single‐chain antibody and
encapsulating a normal human wild‐type p53 DNA sequence to restore the wild‐type p53
function and downmodulate MGMT activity in order to increase the sensitivity of tumor cells
to alkylating agents.
Concerning the different routes of administration, intravenous among the systemic routes and
CED and intrathecal delivery among the local routes have even made its way into clinical trials
for nanoparticle administration.
In conclusion, clinical implementation of nanomedicines for patients with brain tumors is still
in its infancy. However, further clinical studies of brain‐targeted nanomedicines are warranted
in the future, with increasing incidences of CNS cancers, many of whom being terrible rapidly
progressing and so far untreatable tumors. Hence, the accumulation of data about the CNS
physiology and about relevant receptors, the widening therapeutic armamentarium of drugs
potentially useful in CNS chemotherapy, the alternative routes for administration and the
estimation of the brain permeability with in vitro BBB models to early triage the potential of
nanomedicines for optimum therapy of brain tumors envisage nanomedicines as a forthcom‐
ing routine approach [114].
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